Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

Stocks Recover on Fed Rate Cut Expectations

View original at nasdaq.com
Stocks Recover on Fed Rate Cut Expectations The S&P 500 Index ($SPX) (SPY) today is up by +0.18%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.47%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -0.06%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cut full-year adjusted EPS forecast to $1.94-$2.04 from previous estimate of $2.35-$2.45, well below consensus of $2.37

    80% confidence
  • Q3 earnings rose 14.6%, more than doubling expectations of 7.2% y/y

    80% confidence
  • Upgraded Vertex Pharmaceuticals to overweight from equal weight with price target of $516

    80% confidence
  • He will announce his selection for the new Fed Chair in early 2026

    80% confidence
  • 83% of reporting S&P 500 companies exceeded forecasts, on course for the best quarter since 2021

    80% confidence
  • Raised 2026 comparable sales growth forecast to low single digits from previous estimate of flat

    80% confidence
  • Upgraded Astera Labs to buy with price target of $275

    80% confidence
  • Forecasted Q4 revenue of $251 million to $252 million, midpoint below consensus of $251.9 million

    80% confidence
  • Microsoft is reducing its AI software sales quotas amid consumer resistance to newer products

    80% confidence
  • Kevin Hassett is seen as the likely choice to succeed Powell as Fed Chair

    80% confidence
  • Q3 adjusted EPS forecasted at 40 cents, above consensus of 37 cents

    80% confidence
  • Forecasted Q4 operating income of $220 million to $230 million, above consensus of $214.5 million

    80% confidence
  • Upgraded Stellantis to buy from neutral with price target of $12

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com
Stocks Recover on Fed Rate Cut Expectations — Source | Via News | Finance Via News